Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'RECOMBINANT FACTOR-VIII' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 109 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Mauser-Bunschoten, EP; van der Bom, JG; Bongers, M; Twijnstra, M; Roosendaal, G; Fischer, K; van den Berg, HM
      Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A

      HAEMOPHILIA
    2. Yoshioka, A; Shima, M; Fukutake, K; Takamatsu, J; Shirahata, A
      Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan

      HAEMOPHILIA
    3. Ghosh, K; Shetty, S; Kulkarni, B; Nair, S; Pawar, A; Khare, A; Baindur, S; Mohanty, D
      Development of inhibitors in patients with haemophilia from India

      HAEMOPHILIA
    4. Haya, S; Lopez, MF; Aznar, JA; Batlle, J
      Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry

      HAEMOPHILIA
    5. Mondorf, W; Klinge, J; Luban, NLC; Bray, G; Saenko, E; Scandella, D
      Low factor VIII recovery in haemophilia A patients without inhibitor titreis not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay

      HAEMOPHILIA
    6. Calvez, T; Biou, M; Costagliola, D; Jullien, AM; Laurian, Y; Rossi, F; Rothschild, C; Sie, P
      The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system

      HAEMOPHILIA
    7. Mauser-Bunschoten, EP; Roosendaal, G; Van den Berg, HM
      Product choice and haemophilia treatment in the Netherlands

      HAEMOPHILIA
    8. Hoots, WK
      Safety issues affecting hemophilia products

      TRANSFUSION MEDICINE REVIEWS
    9. Wu, HY; Reding, M; Qian, J; Okita, DK; Parker, E; Lollar, P; Hoyer, LW; Conti-Fine, BM
      Mechanism of the immune response to human factor VIII in murine hemophiliaA

      THROMBOSIS AND HAEMOSTASIS
    10. Bjorkman, S; Berntorp, E
      Pharmacokinetics of coagulation factors clinical relevance for patients with haemophilia

      CLINICAL PHARMACOKINETICS
    11. Mannucci, PM; Tuddenham, EGD
      Medical progress - The hemophilias - From royal genes to gene therapy

      NEW ENGLAND JOURNAL OF MEDICINE
    12. Lorenzo, JI; Lopez, A; Altisent, C; Aznar, JA
      Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age

      BRITISH JOURNAL OF HAEMATOLOGY
    13. Alsolaiman, MM; Chang, K; Arjomand, H; Oza, R; Costacurta, G
      Acute left anterior descending artery occlusion in a hemophiliac A patientduring recombinant factor VIII infusion: Treatment with coronary angioplasty

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    14. Lynch, TJ
      Biotechnology: alternatives to human plasma-derived therapeutic proteins

      BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
    15. El Alfy, MS; Tantawy, AAG; Ahmed, MH; Abdin, IA
      Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction

      HAEMOPHILIA
    16. White, B; Cotter, M; Byrne, M; O'Shea, E; Smith, OP
      High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice?

      HAEMOPHILIA
    17. Santagostino, E; Mannucci, PM; Bonomi, AB
      Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy

      HAEMOPHILIA
    18. Goldsmith, JC
      Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates

      BLOOD COAGULATION & FIBRINOLYSIS
    19. Shirahata, A; Fukutake, K; Takamatsu, J; Shima, M; Yoshioka, A
      Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A

      INTERNATIONAL JOURNAL OF HEMATOLOGY
    20. Lundblad, RL; Kingdon, HS; Mann, KG; White, GC
      Issues with the assay of factor VIII activity in plasma and factor VIII concentrates

      THROMBOSIS AND HAEMOSTASIS
    21. Abshire, TC; Brackmann, HH; Scharrer, I; Hoots, K; Gazengel, C; Powell, JS; Gorina, E; Kellermann, E; Vosburgh, E
      Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - Results of a multicenter, international, clinical investigation

      THROMBOSIS AND HAEMOSTASIS
    22. Vlot, AJ; Mauser-Bunschoten, EP; Zarkova, AG; Haan, E; Kruitwagen, CLJJ; Sixma, JJ; van den Berg, HM
      The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A

      THROMBOSIS AND HAEMOSTASIS
    23. Knobe, KE; Villoutreix, BO; Tengborn, L; Petrini, P; Ljung, RCR
      Factor VIII inhibitors in two families with mild haemophilia A: Structuralanalysis of the mutations

      HAEMOSTASIS
    24. Bachinger, T; Riese, U; Eriksson, R; Mandenius, CF
      Monitoring cellular state transitions in a production-scale CHO-cell process using an electronic nose

      JOURNAL OF BIOTECHNOLOGY
    25. Emilien, G; Maloteaux, JM; Penasse, C; Goodeve, A; Casimir, C
      Haemophilias: advances towards genetic engineering replacement therapy

      CLINICAL AND LABORATORY HAEMATOLOGY
    26. Fakharzadeh, SS; Kazazian, HH
      Correlation between factor VIII genotype and inhibitor development in hemophilia A

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    27. Kaplan, J; Genyea, C; Secord, E
      Potential for prevention of inhibitor formation by immune tolerance

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    28. Aledort, LM
      Immune tolerance induction: Is it cost effective? We know too little

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    29. Ho, AYL; Height, SE; Smith, MP
      Immune tolerance therapy for haemophilia

      DRUGS
    30. Colowick, AB; Bohn, RL; Avorn, J; Ewenstein, BM
      Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

      BLOOD
    31. van den Brink, EN; Turenhout, EAM; Bank, CMC; Fijnvandraat, K; Peters, M; Voorberg, J
      Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain

      BLOOD
    32. Moreau, A; Lacroix-Desmazes, S; Stieltjes, N; Saenko, E; Kaveri, SV; D'Oiron, R; Sultan, Y; Scandella, D; Kazatchkine, MD
      Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophiliaA and in normal polyclonal human IgG

      BLOOD
    33. Lee, JH; Kim, HW; Kwon, YB; Kang, MS; Choi, DW; Na, JH; Kwon, OK; Youn, HJ; Han, HJ; Byun, TH; Park, SY; Chun, BH; Pyun, JH; An, GH; Lee, YJ; Cho, MH
      General pharmacology studies on beta-domain deleted recombinant factor VIII

      ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
    34. Scharrer, I; Bray, GL; Neutzling, O
      Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates

      HAEMOPHILIA
    35. Hay, JW; Ernst, RL; Kessler, CM
      Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A

      HAEMOPHILIA
    36. Manno, CS
      Treatment options for bleeding episodes in patients undergoing immune tolerance therapy

      HAEMOPHILIA
    37. Chiang, GG; Rubin, HL; Cherington, V; Wang, T; Sobolewski, J; McGrath, CA; Gaffney, A; Emami, S; Sarver, N; Levine, PH; Greenberger, JS; Hurwitz, DR
      Bone marrow stromal cell-mediated gene therapy for hemophilia A: In vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648

      HUMAN GENE THERAPY
    38. Niemann, H; Halter, R; Carnwath, JW; Herrmann, D; Lemme, E; Paul, D
      Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep

      TRANSGENIC RESEARCH
    39. Vianello, F; Tison, T; Tagariello, G; Zerbinati, P; Zanon, E; Scarano, L; Girolami, A
      Serological markers of autoimmunity in patients with hemophilia A: the role of hepatitis C virus infection, alpha-interferon and factor VIII treatment in skewing the immune system toward autoreactivity

      BLOOD COAGULATION & FIBRINOLYSIS
    40. Zanon, E; Zerbinati, P; Girolami, B; Bertomoro, A; Girolami, A
      Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates

      BLOOD COAGULATION & FIBRINOLYSIS
    41. Parquet, A; Laurian, Y; Rothschild, C; Navarro, R; Guerois, C; Gay, V; Durin, A; Peynet, J; Sultan, Y
      Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate

      THROMBOSIS AND HAEMOSTASIS
    42. Kaufman, RJ; Pipe, SW
      Regulation of factor VIII expression and activity by von Willebrand factor

      THROMBOSIS AND HAEMOSTASIS
    43. Gill, JC
      The role of genetics in inhibitor formation

      THROMBOSIS AND HAEMOSTASIS
    44. Reding, MT; Wu, H; Krampf, M; Okita, DK; Diethelm-Okita, BM; Key, NS; Conti-Fine, BM
      CD4(+) T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects

      THROMBOSIS AND HAEMOSTASIS
    45. Connelly, S; Andrews, JL; Gallo-Penn, AM; Tagliavacca, L; Kaufman, RJ; Kaleko, M
      Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice

      THROMBOSIS AND HAEMOSTASIS
    46. Qian, JJ; Borovok, M; Bi, L; Kazazian, HH; Hoyer, LW
      Inhibitor antibody development and T cell response to human factor VIII inmurine hemophilia A

      THROMBOSIS AND HAEMOSTASIS
    47. Scheiflinger, F; Dorner, F
      Recent advances in the understanding of the molecular biology of hemophilia A: Possible implications towards a more effective therapeutic regime

      WIENER KLINISCHE WOCHENSCHRIFT
    48. Berntorp, E
      Other ongoing rFVIII PUP studies

      VOX SANGUINIS
    49. Mannucci, PM; Tuddenham, EGD
      The hemophilias: Progress and problems

      SEMINARS IN HEMATOLOGY
    50. Saenko, EL; Yakhyaev, AV; Mikhailenko, I; Strickland, DK; Sarafanov, AG
      Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism

      JOURNAL OF BIOLOGICAL CHEMISTRY
    51. Hay, CRM
      Why do inhibitors arise in patients with haemophilia A?

      BRITISH JOURNAL OF HAEMATOLOGY
    52. Yee, TT; Pasi, KJ; Lee, CA
      Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97

      BRITISH JOURNAL OF HAEMATOLOGY
    53. Oren, H; Yaprak, I; Irken, G
      Factor VIII inhibitors in patients with hemophilia A

      ACTA HAEMATOLOGICA
    54. Pock, K; Rizzi, A; Josic, D
      Use of high-resolution techniques for the characterization of clotting factor VIII

      JOURNAL OF CHROMATOGRAPHY A
    55. TEITEL JM; CARD R; STRAWCZYNSKI H
      LABORATORY AND CLINICAL MARKERS OF HIV-INFECTION IN A NATIONAL HEMOPHILIA COHORT TREATED WITH RECOMBINANT FACTOR-VIII CONCENTRATE

      Haemophilia
    56. HAYA S; LORENZO JI; DASI MA; AZNAR JA
      DEVELOPMENT OF A FACTOR-VIII INHIBITOR IN A NEWBORN HEMOPHILIAC

      Haemophilia
    57. TEITEL JM
      SAFETY OF COAGULATION-FACTOR CONCENTRATES

      Haemophilia
    58. AZNAR JA; LORENZO JI; MOLINA R; HAYA S; QUEROL F; DASI MA
      ZERO INCIDENCE OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED HEMOPHILIA-A, HIV-NEGATIVE PATIENTS UPON EXPOSURE TO A PLASMA-DERIVED HIGH-PURITY AND DOUBLE VIRAL INACTIVATED FACTOR-VIII CONCENTRATE

      Haemophilia
    59. ALEDORT LM; DIMICHELE DM
      INHIBITORS OCCUR MORE FREQUENTLY IN AFRICAN-AMERICAN AND LATINO HEMOPHILIACS

      Haemophilia
    60. Hurst, D; Zabor, S; Malianni, D; Miller, D
      Evaluation of recombinant factor VIII (Kogenate (R)) stability for continuous infusion using a minipump infusion device

      HAEMOPHILIA
    61. DIDIER ME; FISCHER S; MAKI DG
      RECONSTITUTED RECOMBINANT FACTOR-VIII CAN BE SAFELY INFUSED CONTINUOUSLY FOR AT LEAST 3 DAYS - IT IS A POOR MICROBIAL-GROWTH MEDIUM

      Blood coagulation & fibrinolysis
    62. MANDENIUS CF; HAGMAN A; DUNAS F; SUNDGREN H; LUNDSTROM I
      A MULTISENSOR ARRAY FOR VISUALIZING CONTINUOUS STATE TRANSITIONS IN BIOPHARMACEUTICAL PROCESSES USING PRINCIPAL COMPONENT ANALYSIS

      Biosensors & bioelectronics
    63. DiMichele, D; Neufeld, EJ
      Hemophilia - A new approach to an old disease

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    64. HAY CRM; LUDLAM CA; COLVIN BT; HILL FGH; PRESTON FE; WASSEEM N; BAGNALL R; PEAKE IR; BERNTORP E; BUNSCHOTEN EPM; FIJNVANDRAAT K; KASPER CK; WHITE G; SANTAGOSTINO E
      FACTOR-VIII INHIBITORS IN MILD AND MODERATE-SEVERITY HEMOPHILIA-A

      Thrombosis and haemostasis
    65. VLOT AJ; KOPPELMAN SJ; BOUMA BN; SIXMA JJ
      FACTOR-VIII AND VON-WILLEBRAND-FACTOR

      Thrombosis and haemostasis
    66. TSUCHIYA H; SHIMA M; YOSHIOKA A
      ANAPHYLACTIC RESPONSE TO FACTOR-VIII PREPARATIONS IN A HEMOPHILIC CHILD WITH AN INHIBITOR OF HIGH-TITER DURING THE TOLERANCE INDUCTION

      European journal of pediatrics
    67. HERLITSCHKA SE; SCHLOKAT U; FALKNER FG; DORNER F
      HIGH EXPRESSION OF A B-DOMAIN DELETED FACTOR-VIII GENE IN A HUMAN HEPATIC CELL-LINE

      Journal of biotechnology
    68. LENTING PJ; VANMOURIK JA; MERTENS K
      THE LIFE-CYCLE OF COAGULATION-FACTOR-VIII IN VIEW OF ITS STRUCTURE AND FUNCTION

      Blood
    69. FIJNVANDRAAT K; CELIE PHN; TURENHOUT EAM; TENCATE JW; VANMOURIK JA; MERTENS K; PETERS M; VOORBERG J
      A HUMAN ALLOANTIBODY INTERFERES WITH BINDING OF FACTOR IXA TO THE FACTOR-VIII LIGHT-CHAIN

      Blood
    70. BJORKMAN S; CARLSSON M
      THE PHARMACOKINETICS OF FACTOR-VIII AND FACTOR-IX - METHODOLOGY, PITFALLS AND APPLICATIONS

      Haemophilia
    71. COLVIN BT
      GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS

      Haemophilia
    72. LIESNER RJ
      PROPHYLAXIS IN HEMOPHILIC CHILDREN

      Blood coagulation & fibrinolysis
    73. BLANCHETTE VS
      RECOMBINANT FACTOR-VIII IN HEMOPHILIA-A - THE CANADIAN EXPERIENCE

      Blood coagulation & fibrinolysis
    74. HANSEN K; KJALKE M; RASMUSSEN PB; KONGERSLEV L; EZBAN M
      PROTEOLYTIC CLEAVAGE OF RECOMBINANT 2-CHAIN FACTOR-VIII DURING CELL-CULTURE PRODUCTION IS MEDIATED BY PROTEASE(S) FROM LYSED CELLS - THE USE OF PULSE LABELING DIRECTLY IN PRODUCTION MEDIUM

      Cytotechnology
    75. YEE TT; WILLIAMS MD; HILL FGH; LEE CA; PASI KJ
      ABSENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA-A AFTER EXPOSURE TO A SINGLE INTERMEDIATE PURITY FACTOR-VIII PRODUCT

      Thrombosis and haemostasis
    76. GILLES JGG; JACQUEMIN MG; SAINTREMY JMR
      FACTOR-VIII INHIBITORS

      Thrombosis and haemostasis
    77. LOLLAR P
      ANALYSIS OF FACTOR-VIII INHIBITORS USING HYBRID HUMAN PORCINE FACTOR-VIII/

      Thrombosis and haemostasis
    78. NEGRIER C; GOUDEMAND J; SULTAN Y; BERTRAND M; ROTHSCHILD C; LAUROUA P
      MULTICENTER RETROSPECTIVE STUDY ON THE UTILIZATION OF FEIBA IN FRANCEIN PATIENTS WITH FACTOR-VIII AND FACTOR-IX INHIBITORS

      Thrombosis and haemostasis
    79. FIJNVANDRAAT K; TURENHOUT EAM; VANDENBRINK EN; TENCATE JW; VANMOURIK JA; PETERS M; VOORBERG J
      THE MISSENSE MUTATION ARG(593)-]CYS IS RELATED TO ANTIBODY-FORMATION IN A PATIENT WITH MILD HEMOPHILIA-A

      Blood
    80. PRESCOTT R; NAKAI H; SAENKO EL; SCHARRER I; NILSSON IM; HUMPHRIES JE; HURST D; BRAY G; SCANDELLA D
      THE INHIBITOR ANTIBODY-RESPONSE IS MORE COMPLEX IN HEMOPHILIA-A PATIENTS THAN IN MOST NONHEMOPHILIACS WITH FACTOR-VIII AUTOANTIBODIES

      Blood
    81. VYAS P; PASI KJ; LEE CA
      SUCCESSFUL LONG-TERM TREATMENT WITH PORCINE FACTOR-VIII OF A PATIENT WITH HEMOPHILIA-A AND AN INHIBITOR TO FACTOR-VIII

      Haemophilia
    82. FRICKHOFEN N; ELLBRUCK D; BIESTER I; JAINTA C; KOERNER K; WOLF H; SEIFREID E
      SIMILAR PREVALENCE OF HEPATITIS-C VIRUS-I NFECTION IN HEMOPHILIA PATIENTS TREATED IN 2 CLINICAL CENTERS IN THE FORMER WESTERN AND EASTERN PART OF GERMANY

      Infusionstherapie und Transfusionsmedizin
    83. SCHOPPMANN A; WAYTES AT
      FACTOR-VIII INHIBITOR AND SEVERITY OF HEMOPHILIA

      Thrombosis and haemostasis
    84. NOE DA
      A MATHEMATICAL-MODEL OF COAGULATION-FACTOR-VIII KINETICS

      Haemostasis
    85. BARKAGAN ZS; BUEVICH EI
      PRESENT-DAY THERAPY AND REHABILITATION OF HEMOPHILIACS WITH IMMUNE INHIBITORS OF ANTITHEMOPHILIA FACTORS

      Gematologia i transfuziologia
    86. DONATH MJSH; LENTING PJ; VANMOURIK JA; MERTENS K
      KINETICS OF FACTOR-VIII LIGHT-CHAIN CLEAVAGE BY THROMBIN AND FACTOR XA - A REGULATORY ROLE OF THE FACTOR-VIII HEAVY-CHAIN REGION LYS713-ARG740

      European journal of biochemistry
    87. ROCK G; ADAMKIEWICZ T; BLANCHETTE V; POON A; SPARLING C
      ACQUIRED VON-WILLEBRAND-FACTOR DEFICIENCY DURING HIGH-DOSE INFUSION OF RECOMBINANT FACTOR-VIII

      British Journal of Haematology
    88. ZIEG PM; COHN SM; BEARDSLEY DS
      NONOPERATIVE MANAGEMENT OF A SPLENIC TEAR IN A JEHOVAH-WITNESS WITH HEMOPHILIA

      The journal of trauma, injury, infection, and critical care
    89. HAY CRM
      FACTOR-VIII INHIBITORS

      Haemophilia
    90. OLDENBURG J; EFFENBERGER W; HAMMERSTEIN U; BRACKMANN HH
      REPORT ON EXPERIENCES WITH 2 RECOMBINANT FACTOR-VIII CONCENTRATES - KOGENATE(R) (BAYER) AND RECOMBINATE(R) (BAXTER)

      Infusionstherapie und Transfusionsmedizin
    91. SUZUKI T; ARAI M; MIYASAKA S; WATANABE J; SUGIMURA D; AMANO K; YAMAGISHI T; KAGAWA K; FUKUE H; FUKUTAKE K
      FACTOR-VIII INHIBITOR DEVELOPED IN A 60-YEAR-OLD PATIENT WITH MILD HEMOPHILIA-A AFTER SURGERY FOR COLON-CANCER

      International journal of hematology
    92. SHIMA M; SAWAMOTO Y; NAKAI H; KAMISUE S; MURAKAMI T; MORICHIKA S; TANAKA I; HAYASHI K; YOSHIOKA A
      MEASUREMENT OF ANTI-FACTOR-VIII IGG, IGG4 AND IGM ALLOANTIBODIES IN PREVIOUSLY UNTREATED HEMOPHILIA-A PATIENTS TREATED WITH RECOMBINANT FACTOR-VIII

      International journal of hematology
    93. GROWE G; AKABUTU J; RITCHIE B; POON MC; WU J; CARD R; ALI K; ISRAELS SJ; RUBINGER M; BLANCHETTE V; TEITEL J; GARVEY B; WALKER I; PAI MH; INWOOD M; DEVEBER L; BRIEN W; LILLICRAP DP; GILES A; DROUIN J; LUKE KH; HERST J; RIVARD G; STRAWCZYNSKI H; JOBIN F; DEMERS C; LEPINE M; ROBINSON S; BARNARD D; SCULLY MF; DOLAN S; RUBIN S; ROSS E; JARDINE L; WHITMAN L; INGRAM L
      HEMOPHILIA AND VON WILLEBRANDS DISEASE .2. MANAGEMENT

      CMAJ. Canadian Medical Association journal
    94. VERBRUGGEN B; NOVAKOVA I; WESSELS H; BOEZEMAN J; VANDENBERG M; MAUSERBUNSCHOTEN E
      THE NIJMEGEN MODIFICATION OF THE BETHESDA ASSAY FOR FACTOR-VIII-C INHIBITORS - IMPROVED SPECIFICITY AND RELIABILITY

      Thrombosis and haemostasis
    95. DONATH MJSH; DELAAF RTM; BIESSELS PTM; LENTING PJ; VANDELOO JW; VANMOURIK JA; VOORBERG J; MERTENS K
      CHARACTERIZATION OF DES-(741-1668)-FACTOR-VIII, A SINGLE-CHAIN FACTOR-VIII VARIANT WITH A FUSION SITE SUSCEPTIBLE TO PROTEOLYSIS BY THROMBIN AND FACTOR XA

      Biochemical journal
    96. SPAARGAREN J; GIESEN PLA; JANSSEN MP; VOORBERG J; WILLEMS GM; VANMOURIK JA
      BINDING OF BLOOD-COAGULATION FACTOR-VIII AND ITS LIGHT-CHAIN TO PHOSPHATIDYLSERINE PHOSPHATIDYLCHOLINE BILAYERS AS MEASURED BY ELLIPSOMETRY/

      Biochemical journal
    97. KJALKE M; HEDING A; TALBO G; PERSSON E; THOMSEN J; EZBAN M
      AMINO-ACID-RESIDUES 721-729 ARE REQUIRED FOR FULL FACTOR-VIII ACTIVITY

      European journal of biochemistry
    98. SCANDELLA D; GILBERT GE; SHIMA M; NAKAI H; EAGLESON C; FELCH M; PRESCOTT R; RAJALAKSHMI KJ; HOYER LW; SAENKO E
      SOME FACTOR-VIII INHIBITOR ANTIBODIES RECOGNIZE A COMMON EPITOPE CORRESPONDING TO C2 DOMAIN AMINO-ACIDS-2248 THROUGH AMINO-ACIDS-2312, WHICH OVERLAP A PHOSPHOLIPID-BINDING SITE

      Blood
    99. VLOT AJ; KOPPELMAN SJ; VANDENBERG MH; BOUMA BN; SIXMA JJ
      THE AFFINITY AND STOICHIOMETRY OF BINDING OF HUMAN FACTOR-VIII TO VON-WILLEBRAND-FACTOR

      Blood
    100. GRAW J; ERFLE V
      FACTOR-VIII PREPARATIONS FREE FROM VIRUSE S

      Deutsche Medizinische Wochenschrift


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 11:17:46